Remdesivir maker Gilead Sciences sees 10% drop in second-quarter sales as demand for non-coronavirus drugs falls
A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California. Gilead Sciences | via REUTERS Gilead Sciences‘ sales fell 10% in the second quarter from a year earlier as demand fell for some of its drugs because of the coronavirus… Read More »